Browse the evidence

Visceral adipose tissue (VAT) is a stronger predictor of fasting insulin than total adiposity (BMI or percent fat) in young adults with normal glucose tolerance, except in lean black men.

For young adults with normal blood sugar, where you carry fat matters more for insulin health than how much you weigh. Measuring your waist circumference is a simple, effective way to assess metabolic risk, especially if you are white or female. However, for lean black men, standard adiposity measures may not accurately reflect insulin sensitivity, suggesting other factors or measurement limitations may be at play.

Chronic aerobic exercise training reverses high-fat diet-induced impairments in the compartmentalization and activation of insulin-signaling components (specifically aPKC and Akt2) in skeletal muscle, thereby restoring insulin-stimulated glucose transport.

If you have developed insulin resistance from a poor diet, consistent aerobic exercise (like brisk uphill walking or jogging) can restore your muscles' ability to respond to insulin. This happens by fixing how key signaling proteins move to the cell surface to let glucose in. Unlike some medications which may not fix these specific cellular defects, exercise directly corrects the machinery.

Overfeeding-induced insulin resistance is driven by the depletion of small, peripherally located intramyocellular lipid droplets and the subsequent accumulation of large lipid droplets and ceramides, rather than by an increase in total intramyocellular lipid content.

If you are concerned about insulin resistance, focus on maintaining physical activity levels that preserve small, peripheral muscle lipid droplets. High physical activity and efficient lipid oxidation are associated with resistance to weight gain and better insulin sensitivity, even during periods of overfeeding. The total amount of fat in your muscles matters less than how your body organizes that fat.

SGLT-2 inhibitors provide kidney protection (slowing eGFR decline, reducing albuminuria) but have limited or no impact on body weight, making them distinct from GLP-1s in treating obesity-related kidney disease.

SGLT-2 inhibitors protect the kidneys by slowing function decline and reducing protein in urine. They are not primarily weight-loss drugs, so they should be used alongside lifestyle changes for obesity.

GLP-1 receptor agonism (liraglutide) sensitizes hypothalamic POMC neurons and ventral tegmental area (VTA) dopaminergic neurons to nicotine, increasing their excitability and contributing to weight loss.

GLP-1 drugs may work better for smokers because they make the brain's reward and hunger centers more responsive to nicotine. This interaction increases the activity of neurons that suppress appetite and burn energy.

Acute systemic hypoglycemia gates and enhances the entry and action of GLP-1 receptor agonists into the brain, leading to increased whole-body lipid oxidation.

If you are using a GLP-1 medication, maintaining stable or slightly lower blood glucose levels (without dangerous hypoglycemia) may help the drug work more effectively in your brain to burn fat. The drug's ability to enter the brain and boost fat burning is significantly enhanced when blood sugar is low, a mechanism that is often impaired in obesity.

Obesity and high-fat diets uncouple the mechanism by which low blood glucose enhances GLP-1 receptor agonist entry into the brain.

If you are obese or eat a high-fat diet, the mechanism that helps GLP-1 drugs enter your brain to burn fat may be less effective. Managing blood glucose and reducing high-fat intake might help restore this natural gating mechanism.

Mechanical unloading, changes in adipokines (increased adiponectin, decreased leptin), and reduced estrogen levels are primary mechanisms driving bone loss during caloric restriction.

Understanding that bone loss is driven by hormonal and mechanical changes helps contextualize the risk. It is not necessarily 'damage' but an adaptation. Addressing it involves mimicking the mechanical load (exercise) and ensuring nutritional support (calcium/vitamin D) that the body might otherwise get from fat tissue.

Leptin, amylin, and adiponectin are recommended as core biomarkers for obesity trials to assess energy homeostasis and predict treatment response.

Obesity trials should measure leptin, amylin, and adiponectin to understand energy homeostasis. Leptin reflects fat stores, amylin promotes satiation, and adiponectin is linked to insulin sensitivity and inflammation.

Intensive glycaemic control reduces microvascular complications (retinopathy, nephropathy, neuropathy) but has limited or potentially harmful effects on macrovascular outcomes and all-cause mortality.

Intensive blood sugar control helps prevent eye, kidney, and nerve damage, but it doesn't significantly prevent heart attacks and may increase the risk of low blood sugar events. Work with your doctor to find a safe blood sugar target that minimizes risks.

Long-term remission of Type 2 Diabetes following metabolic surgery is not sustained for the majority of patients, with remission rates dropping significantly after 5 years.

While surgery often puts Type 2 Diabetes into remission initially, this effect often wears off after several years. Most patients will eventually need to restart diabetes medications to maintain blood sugar control, meaning surgery is a tool for disease management rather than a permanent cure.

There is no evidence supporting the practice of periodizing resistance exercise training for females according to specific phases of the menstrual cycle to promote greater hypertrophic adaptations.

Do not waste time or energy trying to periodize your training based on your menstrual cycle. There is no evidence that training differently in the follicular vs. luteal phase leads to better muscle growth. Stick to a consistent, progressive resistance training program regardless of where you are in your cycle.

Low sleeping energy expenditure (SleepEE) in early pregnancy is associated with insulin resistance and low triiodothyronine (T3) concentrations.

For obese pregnant women, a lower-than-expected metabolic rate is linked to higher insulin resistance and lower thyroid hormone (T3) levels. This suggests that metabolic health issues may drive lower energy expenditure, contributing to weight gain risk.

Specific lipid metabolites, Diacylglycerols (DAGs) and Ceramides, are inversely associated with insulin sensitivity and mitochondrial capacity, suggesting they are the primary drivers of insulin resistance rather than total intramyocellular lipid (IMCL) content.

Your body's ability to handle sugar depends less on how much total fat is stored in your muscles and more on specific toxic fat byproducts called ceramides and DAGs. These toxic lipids build up when you are sedentary or diabetic, blocking insulin signals. Keeping your muscles active helps clear these toxic lipids, improving insulin sensitivity even if total muscle fat remains high.

Vagus nerve stimulation (VNS) and GLP-1 analogs are emerging therapeutic tools that harness brain-body communication to treat obesity and diabetes, though more invasive and long-lasting approaches are needed.

If lifestyle changes are insufficient, medical interventions like GLP-1 analogs (e.g., semaglutide) and vagus nerve stimulation are proven to help reverse metabolic disease by targeting brain-body signals. These are powerful tools, but they may be invasive or expensive. Work with your healthcare provider to determine if these options are appropriate for your specific situation, keeping in mind that more accessible long-term solutions are still being developed.

Current clinical evidence from randomized controlled trials and meta-analyses does not support a causal link between GLP-1 receptor agonist use and an increased risk of thyroid cancer in humans.

If you are considering or taking a GLP-1 medication (like Ozempic or Wegovy) and are worried about thyroid cancer, know that large human studies have not found a proven link. The warning on the label comes from animal studies, not human outcomes. While you should be aware of symptoms, the proven benefits for weight loss and heart health generally outweigh this unproven risk. Do not stop your medication without talking to your doctor, especially if you have a family history of specific thyroid cancers (MTC), which is a separate contraindication.

Setmelanotide treatment is associated with a high incidence of skin hyperpigmentation and injection site reactions, though these are generally mild and manageable.

Patients should expect skin darkening (hyperpigmentation) and injection site reactions as common side effects of Setmelanotide. These are generally mild, do not indicate serious harm, and do not necessarily require discontinuation of therapy, but patients should be counseled on these expected outcomes.

Chronic consumption of high-calorie/obesogenic diets causes maladaptive perturbations in gut-brain signaling, leading to desensitization of vagal afferents and reduced efficacy of appetite-suppressing gut hormones (GLP-1, CCK, PYY), which contributes to the exacerbation of metabolic dysregulation and obesity.

If you have a history of obesity or high-calorie eating, your body's natural 'stop eating' signals (hormones and nerve feedback) may be desensitized. This isn't a failure of willpower; it's a physiological state. To counter this, focus on strategies that naturally stimulate these pathways, such as consuming protein and fiber before carbohydrates (meal sequencing), which has been shown to enhance GLP-1 secretion and improve metabolic control.

High-fat diets, specifically saturated lipids like palmitic acid, disturb gastrointestinal feedback and promote overconsumption independently of food palatability.

Be mindful of high-saturated-fat foods (like those high in palmitic acid). They can disrupt your body's natural 'fullness' signals, leading you to eat more than you need, regardless of how tasty they are. Balancing fats with fiber and protein can help mitigate this effect.

Sympathomimetic drugs (e.g., phentermine) reduce hunger and increase energy expenditure but are limited by adverse cardiovascular and central nervous system effects, leading to withdrawal of many agents from the market.

Older stimulant-based weight loss drugs can work by suppressing appetite and increasing energy expenditure, but they carry higher risks of heart and nervous system side effects. Many have been removed from the market. If prescribed, they are typically for short-term use (12 weeks) and require careful monitoring.

Intensive glucose control using sulphonylurea-insulin therapy in type 2 diabetes reduces long-term cardiovascular events and mortality, with a legacy effect persisting after the active intervention ends.

For patients with type 2 diabetes, achieving tight blood sugar control early in the disease course using intensive therapy (like insulin or sulphonylureas) significantly lowers the risk of heart attacks and death. This benefit persists for at least 10 years after treatment stops, highlighting the importance of not delaying effective therapy.

ChREBP acts as a central regulator linking carbohydrate intake to metabolic disease; its overexpression causes fatty liver and insulin resistance, while its deletion prevents obesity and fatty liver but may cause other metabolic issues like insulin resistance in adipose tissue.

While high sugar intake drives disease via ChREBP, completely eliminating carbohydrates or targeting this pathway aggressively may have unintended metabolic consequences. A balanced approach focusing on reducing HFCS while maintaining adequate complex carbohydrate intake is likely optimal.

Ingesting 3 g/kg body mass of carbohydrate during the 3-hour recovery period following eccentric exercise-induced muscle injury increases local skeletal muscle mRNA expression of pro-inflammatory myokines (IL-6, IL-8, MCP-1) rather than attenuating inflammation.

If you perform heavy eccentric exercise (like heavy leg presses or downhill running), eating carbohydrates immediately after (3g/kg) will increase the genetic signals for inflammation inside your muscles. However, this did not change blood inflammation levels or muscle damage markers in this study. The practical impact on soreness or recovery time is unknown, but you should not avoid carbs for fear of 'increasing inflammation' as the systemic response was unchanged.

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) reduce the risk of macroalbuminuria and renal function decline in patients with Type 2 Diabetes.

GLP-1 medications like semaglutide and liraglutide are not just for blood sugar; they also protect your kidneys. Studies show they significantly lower the risk of developing macroalbuminuria, a key marker of kidney damage.